HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for its HeartBeam System as a tool for assessing potential heart attacks at home. The designation recognizes the potential of HeartBeam's 3D ECG technology to enable physicians to evaluate signs of a possible heart attack when symptoms begin, wherever the patient may be.
The FDA granted the designation within 30 days of HeartBeam's request, ahead of the agency's 60-day statutory review period. According to the company, the designation provides prioritized FDA review and interaction as it advances its heart attack assessment program and is a prerequisite for certain expedited Medicare coverage pathways. HeartBeam expects to seek FDA alignment on the design of a multicenter pivotal study in the coming months and anticipates beginning patient enrollment shortly thereafter. If successful, the study is intended to support a future submission to expand the HeartBeam System indications to include heart attack assessment.
This news matters because heart attacks are a leading cause of death worldwide, and timely assessment is critical for survival. Currently, patients experiencing symptoms must often wait until they reach a hospital to receive an ECG, delaying diagnosis and treatment. HeartBeam's technology aims to change that by providing a portable, cable-free device that can collect ECG signals in 3D from three non-coplanar directions and synthesize them into a 12-lead ECG, the standard for cardiac evaluation. This could allow for earlier detection and faster intervention, potentially saving lives and reducing healthcare costs.
For the industry, the FDA's Breakthrough Device Designation signals a regulatory endorsement of HeartBeam's approach, which could accelerate its path to market and encourage further innovation in remote cardiac monitoring. The designation also opens doors to expedited Medicare coverage, which is crucial for adoption and reimbursement. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to technology enablement. For more details on the cleared indications, refer to the company's Cleared Indications for Use.
Investors and industry watchers can stay updated on HeartBeam's progress through its newsroom at https://nnw.fm/BEAT. The full press release is available at https://nnw.fm/FxKxf.
The announcement was distributed by NetworkNewsWire, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN, which provides services including editorial syndication to 5,000+ outlets and social media distribution. For full disclaimers, visit https://www.NetworkNewsWire.com/Disclaimer.
